Literature DB >> 12483326

Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.

Wataru Watanabe1, Rika Kuwabara, Toshinori Nakahara, Osamu Hamasaki, Ikuo Sakamoto, Koji Okada, Atsushi Minamoto, Hiromu K Mishima.   

Abstract

BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood. With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year. Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen. Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known. However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported. CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe. He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection. Various ocular symptoms and findings caused by carboplatin toxicity were seen.
RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks. Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.
CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity. It is recommended that further studies and investigations are undertaken in the effort to minimize such severe side effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12483326     DOI: 10.1007/s00417-002-0573-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  7 in total

1.  Severe Periocular Edema after Intraarterial Carboplatin Chemotherapy for Retinoblastoma in a Rabbit (Oryctolagus cuniculus) Model.

Authors:  Tai L Oatess; Patty H Chen; Anthony B Daniels; Lauren E Himmel
Journal:  Comp Med       Date:  2020-03-11       Impact factor: 0.982

Review 2.  Effects of Brain Tumors on Vision in Children.

Authors:  Jason H Peragallo
Journal:  Int Ophthalmol Clin       Date:  2018

3.  Vascular distribution of glioblastoma multiforme at diagnosis.

Authors:  K Yohay; D S Wolf; L J Aronson; M Duus; E R Melhem; K J Cohen
Journal:  Interv Neuroradiol       Date:  2013-03-04       Impact factor: 1.610

4.  Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review.

Authors:  Ying Li; Yanping Li; Junyu Li; Guoliang Pi; Wenyong Tan
Journal:  Onco Targets Ther       Date:  2014-07-31       Impact factor: 4.147

5.  Treatment Outcomes of Locally Advanced Squamous Cell Carcinoma of the Ethmoid Sinus Treated with Anterior Craniofacial Resection or Chemoradiotherapy.

Authors:  Takeharu Ono; Norimitsu Tanaka; Hirohito Umeno; Kiyohiko Sakata; Motohiro Morioka; Yoko Ohmaru; Hideaki Rikimaru; Noriyuki Koga; Kensuke Kiyokawa; Shun-Ichi Chitose; Buichiro Shin; Takeichiro Aso; Hidehiro Etoh; Toshi Abe
Journal:  Case Rep Oncol       Date:  2017-04-18

6.  Bilateral blindness with secondary retinitis pigmentosa following postoperative docetaxel and platinum combination chemotherapy in primary small-cell carcinoma of the endometrium: An unusual case report and review of the literature.

Authors:  Qiong-Lan Tang; Jia Liu; Li Zuo; Cong Chi; Hui-Yu Dong; Xiao-Xia Jiang; Xue-Feng Jiang
Journal:  Mol Clin Oncol       Date:  2017-02-24

7.  Carboplatin-Induced Bilateral Papilledema: A Case Report.

Authors:  N Fischer; J Stuermer; B Rodic; M Pless
Journal:  Case Rep Oncol       Date:  2009-04-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.